Amphastar Q3 2024 revenue up 5.9% to $191.2M; adjusted EPS down to $0.96

Amphastar Pharmaceuticals, Inc.

2024-Q3 EPS reported $2.32 revenue$545,444,000

Net revenues $191.2M vs $180.6M in Q3 2023, up 5.9%.
GAAP net income $40.4M ($0.78 diluted EPS) vs $49.2M ($0.91) year ago.
Adjusted non-GAAP net income $49.6M ($0.96 diluted EPS) vs $61.9M ($1.15).
Growth driven by BAQSIMI and Primatene MIST; Primatene on track for $100M annual sales.
No updated guidance provided in the release.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.